

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN DERMATOLOGICAL
TREATMENT DEVICES AND
COMPONENTS THEREOF**

Investigation No. 337-TA-1356

**NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL
DETERMINATION TERMINATING CLAIMS FROM THE INVESTIGATION**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 43) of the presiding administrative law judge (“ALJ”), terminating the investigation as to claim 1 of U.S. Patent No. 10,058,379 (“the ’379 patent”) and claims 6 and 17 of U.S. Patent No. 10,869,812 (“the ’812 patent”) based on Complainant Serendia, LLC’s (“Serendia”) withdrawal of those claims.

FOR FURTHER INFORMATION CONTACT: Benjamin S. Richards, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone (202) 708-5453. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on April 6, 2023. 88 FR 20551 (Apr. 6, 2023). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain dermatological treatment devices by reason of infringement of certain claims of U.S. Patent No. 9,480,836; the ’379 patent; U.S. Patent No. 11,406,444; U.S. Patent No. 9,320,536; U.S. Patent No. 9,775,774; and the ’812 patent. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The Commission’s notice of investigation named as respondents Sung Hwan E&B Co., LTD. d/b/a SHEnB Co. LTD of Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix, AZ; Cartessa Aesthetics, LLC of Melville, NY; Lutronic

Corporation of Goyang-si, Republic of Korea; Lutronic Aesthetics, Inc., also known as Lutronic, Inc. of Billerica, MA; Lutronic, LLC of Billerica, MA; Ilooda, Co., Ltd. of Anyang-si, Republic of Korea; Cutera, Inc. of Brisbane, CA; Jeisys Medical Inc. of Seoul, Republic of Korea; Cynosure, LLC of Westford, MA; Rohrer Aesthetics, LLC of Homewood, AL; Rohrer Aesthetics, Inc. of Homewood, AL; EndyMed Medical Ltd. of Caesarea, Israel; EndyMed Medical, Ltd. of New York, NY; and EndyMed Medical, Inc. of Freehold, NJ. *Id.* at 20552. The Office of Unfair Import Investigations is also participating in the investigation. *Id.*

On November 8, 2023, the ALJ issued the subject ID, which grants an unopposed motion by Serendia to terminate claim 1 of the '379 patent and claims 6 and 7 of the '812 patent from the investigation. The ID finds that the motion complies with Commission's rules and that no party has identified any extraordinary circumstances that would justify denying the motion. No petitions for review of the ID have been received.

The Commission has determined not to review the subject ID. Claim 1 of the '379 patent and claims 6 and 7 of the '812 patent are terminated from this investigation.

The Commission vote for this determination took place on December 8, 2023.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.



Lisa R. Barton
Secretary to the Commission

Issued: December 11, 2023